$3.00
+0.28(10.48%)
Mkt Cap $168M
$0.60
$3.69
52-Week Range
At a Glance
AI-generatedFiscal 2025 was a challenging year for Connect Biopharma marked by sharp revenue declines and expanded losses as we accelerate development of lead candidate rademikibart.
Revenue breakdown: License (93.5%), Clinical Trial Reports (6.5%).
8-K
Connect Biopharma reported 2025 full-year financial results with $55.5 million net loss, positive Phase 1 IV rademikibart data in asthma/COPD, and $20.2 million equity financing extending cash runway into second half of 2027.$168M
Market Cap
$2M
Revenue
-$36M
Net Income
Employees62
Fundamentals
How The Business Makes Money
Revenue by Segment
License93.5%($24M)
Clinical Trial Reports6.5%($2M)
Activity
What Changed Recently
Company Profile
CIK0001835268
ISINKYG235491019
CUSIPG23549101
Phone86 512 5357 7866
AddressEast R&D Building, Taicang, 215400, CN
SEC EDGAR